Table 2.
Novel prediction by DeepARV-Sim and DeepARV-ChemBERTa
| ARV – Comedication | DeepARV-Sim | DeepARV-ChemBERTa | Comedication Drug Class | Supported Evidence (NICE, Drugs.com) |
|---|---|---|---|---|
| Efavirenz – Esomeprazole* | X | X | Gastrointestinal Agents | Risk of altered drug metabolism. |
| Efavirenz – Lansoprazole* | X | X | ||
| Efavirenz – Omeprazole* | X | X | ||
| Efavirenz – Pantoprazole* | X | |||
| Efavirenz – Oxcarbazepine | X | X | ||
| Efavirenz – Ondansetron* | X | Risk of QT prolongation. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. | ||
| Efavirenz – Canagliflozin | X | Anti-diabetics | Risk of decreasing the exposure to the comedication. Manufacturer advises adjust Canagliflozin dose. | |
| Efavirenz – Chlorpromazine* | X | Antipsychotics, Neuroleptics | Risk of QT prolongation. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. | |
| Efavirenz – Formoterol* | X | Bronchodilators | Risk of hypokalaemia caused by the comedication (potentially increasing the risk of torsade de pointes) when taking with Efavirenz. | |
| Efavirenz – Olodaterol | X | |||
| Efavirenz – Furosemide* | X | Hypertension, Heart Failure Agents | Risk of hypokalaemia caused by the comedication (potentially increasing the risk of torsade de pointes) when taking with Efavirenz. | |
| Efavirenz – Levonorgestrel (IUD)* | X | Contraceptives, HRT | Risk of decreasing the efficacy of the comedication | |
| Lopinavir/Ritonavir – Buprenorphine | X | X | Analgesics | Risk of increasing the concentration of the comedication. Manufacturer advises to monitor and adjust the dose. |
| Lopinavir/Ritonavir – Doxycycline | X | X | Antibacterials | Risk of hepatotoxicity. |
| Lopinavir/Ritonavir – Miconazole | X | Antifungals | Risk of increasing the concentration of the ARVs. Manufacturer advises use with caution and adjusted dose. | |
| Lopinavir/Ritonavir – Caspofungin | X | Risk of hepatotoxicity. | ||
| Lopinavir/Ritonavir – Dactinomycin | X | X | Cancer Therapies | Risk of hepatotoxicity. |
| Lopinavir/Ritonavir – Lenalidomide | X | |||
| Lopinavir/Ritonavir – Oxandrolone | X | X | Steroids | Risk of hepatotoxicity. |
| Lopinavir/Ritonavir – Hydrocortisone* | X | Risk of increasing the exposure to the comedication. Manufacturer advises avoid or monitor adverse effects. | ||
| Lopinavir/Ritonavir – Thalidomide | X | X | Other | Risk of hepatotoxicity. |
| Lopinavir/Ritonavir – Acitretin | X | |||
| Lopinavir/Ritonavir – Cabergoline* | X | Risk of increasing the concentration of comedication. | ||
| Lopinavir/Ritonavir – Almotriptan | X | Risk of increasing the exposure of the comedication. | ||
| Lopinavir/Ritonavir – Levonorgestrel (IUD) | X | Contraceptives, HRT | Risk of decreasing efficacy of the comedication. | |
| Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (DRV/c/FTC/TAF) – Acenocoumarol | X | X | Anti-coagulant, Anti-platelet | Risk of altered the anticoagulant effect of comedication. Manufacturer advises monitoring. |
| DRV/c/FTC/TAF – Clotrimazole | X | X | Antifungals | Risk of increasing the concentration of Darunavir and Cobicistat. Caution is warranted and clinical monitoring is recommended by the European Medicines Agency (EMA). |
| DRV/c/FTC/TAF – Almotriptan* | X | Antimigraine Agents | Risk of increasing the exposure to the comedication. | |
| DRV/c/FTC/TAF – Cabergoline* | X | X | Other | Risk of increasing the exposure to the comedication. |
| DRV/c/FTC/TAF – Atovaquone | X | |||
| DRV/c/FTC/TAF – Naloxone | X | X | Risk of increasing the concentration of the comedication. Dose adjustment may not be necessary but a careful clinical monitoring for signs of opiate toxicity is recommended by the EMA. | |
| DRV/c/FTC/TAF – Hydrocortisone* | X | Steroids | Risk of increasing exposure to comedication. Manufacturer advises avoid or monitor adverse effects. | |
| Raltegravir – Darunavir/Ritonavir (DRV/r) | X | X | ARVs | Risk of clinical rash, which was more commonly observed with regimens containing Raltegravir and Darunavir compared to those containing Raltegravir without darunavir or darunavir without Raltegravir (EMA). |
*These DDIs have been re-classified and updated on the Liverpool HIV Drug Interaction database, https://www.hiv-druginteractions.org (Last review on January 12, 2024).